Comparison between Serum Aldosterone Levels in Class I-II and Class III-IV Functional Heart Failure Patients
DOI:
https://doi.org/10.3889/oamjms.2020.5541Keywords:
aldosterone, angiotensin-converting enzyme inhibitors, blood pressure, myocardium, heart failureAbstract
BACKGROUND: Aldosterone plays a role in the initiation and development of heart failure (HF). During congestive HF, the initial reduction in cardiac output stimulates the renin-angiotensin-aldosterone system, which in turn exerts additional stress on the heart.
AIM: This research was aimed to explore the comparison of aldosterone levels between Class I-II functional HF and Class III-IV HF to optimize therapy in cases of HF.
METHODS: The study design is an observational study with a cross-sectional approach. This study was conducted at the Department of Internal Medicine Dr. Moh Hoesin Hospital in Palembang, Indonesia. All patients diagnosed with functional III-IV functional HF disease based on symptoms clinical, physical, and electrocardiography (ECG) examination and history of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blocker (ARB) treatment are willing to join the research by signing informed consent.
RESULTS: There is no confounding variable that has a significantly different effect on the group I-II and III-IV functional HF groups. Aldosterone levels also did not show a significant difference between the group New York Heart Association (NYHA) I-II active HF group and the NYHA Class III-IV functional HF group (p = 0.445).
CONCLUSION: Serum aldosterone levels in patients with Class I-II functional HF and those with Class III-IV functional HF who consumed ACEIs or ARBs were not significantly different.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Julie HB, Anderson ME. Aldosterone and cardiovascular disease: The heart of the matter. In: Trends Endocrinol Metabolism. 1st ed. Chicago: Northwestern University; 2013. p. 21-30. DOI: https://doi.org/10.1016/j.tem.2012.09.004
Yancy CW, Jessup M, Bozkurt M, Buttler J, Casey D Jr., Colvin MM, et al. 2017 ACCF/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136:e137- 61. https://doi.org/10.1161/cir.0000000000000460 PMid:28455343 DOI: https://doi.org/10.1161/CIR.0000000000000460
Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L,Sendon JL, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: The SHIFT study. Eur Heart J. 2016;33(22):2813-20. https://doi.org/10.1093/eurheartj/ehs259 PMid:22927555 DOI: https://doi.org/10.1093/eurheartj/ehs259
Braunwald E. Heart failure: State of the art paper. J Am Coll Cardiol. 2013;1(1):1-20. DOI: https://doi.org/10.1016/j.jchf.2012.10.002
Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, et al. Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014;16(1):76-85. https:// doi.org/10.1093/eurjhf/hft129 PMid:23928650 DOI: https://doi.org/10.1093/eurjhf/hft129
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Develop in collaboration with the heart failure association. Eur J Heart. 2012;14(8):803- 69. https://doi.org/10.3410/f.718489795.793497182 DOI: https://doi.org/10.3410/f.718489795.793497182
Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186(1):1-20. PMid:16002531 DOI: https://doi.org/10.1677/joe.1.06017
McKelvie RS, Rouleau JL, White M, Afzal R, Young JB, Maggioni AP, et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2013;24(19):1727-34. https://doi.org/10.1016/s0195-668x(03)00477-9 PMid:14522567 DOI: https://doi.org/10.1016/S0195-668X(03)00477-9
Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol. 2014;21(7):67-74. PMid:15134803
Lip GYH, Gibbs CR, Beevers DG. ABC of heart failure: Aetiology. BMJ. 2000;320(7227):104-7. https://doi.org/10.1136/sbmj.000219 PMid:10625270 DOI: https://doi.org/10.1136/bmj.320.7227.104
Izzo JL, Gradman AH. Mechanism and management of hypertensive heart disease: From left ventricular hypertrophy to heart failure. Med Clin North Am. 2014;88:1257-71. https://doi.org/10.1016/j.mcna.2004.06.002 PMid:15331316 DOI: https://doi.org/10.1016/j.mcna.2004.06.002
Figueroa MS, Peters J. Congestive heart failure: Diagnosis, pathophysiology, therapy, and implications for respiratory care. In: Respir Care. 3rd ed. Texas: The University of Texas Health Science Center; 2016. p. 403-12.
Rodeheffer R. Cardiomyopathies in the adult (dilated, hypertrophic, and restrictive). In: Dec GW, editor. Heart Failure a Comprehensive Guide to Diagnosis and Treatment. New York: Marcel Dekker; 2015. p. 137-56. https://doi.org/10.1201/b14176-11 DOI: https://doi.org/10.1201/b14176-11
Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure: Pathophysiology. BMJ. 2010;320(7228):167-70. https://doi.org/10.1136/bmj.320.7228.167 PMid:10634740 DOI: https://doi.org/10.1136/bmj.320.7228.167
McNamara DM. Neurohormonal and cytokine activation in heart failure. In: Dec GW, editor. Heart Failure a Comprehensive Guide to Diagnosis and Treatment. New York: Marcel Dekker; 2015. p. 117-36. https://doi.org/10.1201/b14176-10 DOI: https://doi.org/10.1201/b14176-10
Santoso A, Erwinanto, Munawar M, Suryawan R, Rifqi S, Soerianata S. Diagnosis and treatment of acute heart failure. Jakarta: EGC; 2007. p. 120-35.
Mann DL, Murali C. Heart failure: Pathophysiology and diagnosis. In: Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw- Hill; 2015. p. 1500-6.
King M, Kingery J, Casey B. Diagnosis and Evaluation of Heart Failure. 2nd ed. Kentucky, New York: American Academy of Family Physician, McGraw-Hill; 2012. p. 1020-48.
Yang M. Aldosterone. In: Researcher. 1st ed. New York: McGraw- Hill; 2009. p. 89-93.
Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31(10):1237-47. https://doi.org/10.1093/eurheartj/ehq019 PMid:20200015 DOI: https://doi.org/10.1093/eurheartj/ehq019
Murin J. Cardiovascular effect of aldosterone. Bratisl Lek Listy. 2015;106(1):3-19.
Ruster C, Wolf G. Renin angiotensin aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17(11):2985-91. https://doi.org/10.1681/asn.2006040356 PMid:17035613 DOI: https://doi.org/10.1681/ASN.2006040356
Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(Suppl B):9-20. https://doi.org/10.18553/ jmcp.2007.13.s8-b.9 PMid:17970613 DOI: https://doi.org/10.18553/jmcp.2007.13.s8-b.9
Kobayashi M, Stienen S, Maaten J, Dickstein K, Samani NJ, Lang CC, et al. Clinical determinants and prognostic imlications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure. 2020;7:953-63. https://doi.org/10.1002/ehf2.12634 PMid:32167681 DOI: https://doi.org/10.1002/ehf2.12634
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Rizki Darmawan, Taufik Indrajaya, Erial Bahar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
